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My hand is weary with writing, 
My sharp quill is not steady, 
My slender-beaked pen jets forth 
A black draught of shining dark-blue ink. 
  
A stream of wisdom of blessèd God 
Springs from my fair-brown shapely hand: 
On the page it squirts its draught 
Of ink of the green-skinned holly. 
  
My little dripping pen travels 
Across the plain of shining books, 
Without ceasing for the wealth of the great― 
Whence my hand is weary with writing. 
11th-century poem in honour of St Colum (nästan colon) Cille about Book of Kells 
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ABSTRACT 
________________________________________________________________________ 
 
In Sweden, about 6000 patients get a colorectal cancer diagnosis annually. Advances in man-
agement of both colon and rectal cancer have reduced mortality even though the incidences 
are increasing. To improve outcome further, it is important to identify prognostic and predic-
tive factors for personalized, optimal surgery and to guide adjuvant treatment decisions. By 
selecting the right therapy combined with selection of the right patients, one can obtain indi-
vidualization. Potential drug targets prevalent in primary tumors and metastases are of inter-
est as well. HER3 is a transmembranous, epidermal growth factor receptor that is over ex-
pressed in colon and rectal cancer. It affects cellular proliferation, differentiation and migra-
tion in embryogenesis and in oncogenesis through activation of intracellular signal pathways.  
This thesis investigates HER expression and prognosis in colon and rectal cancer, as well as 
in correlated lymph node and liver metastases. HER3´s association to a combination of bi-
omarkers, MMR expression and HLA-A*02 genotype, is examined related to prognosis. 
Two cohorts of patients have been available for our investigation. Immunohistochemical 
(IHC) detection of HER3 and MMR expression was performed in a group of Swedish pa-
tients with primary colon and rectal cancer of stage II and III. The patients derived from a 
randomized Nordic trial aiming to evaluate additive effect of adjuvant chemotherapy to sur-
gery. HER3 expression was also detected by IHC in a different group of patients, resected for 
both colorectal cancer (CRC) and corresponding liver metastases. FISH analysis was done to 
examine if gene amplification occurred associated to HER3 expression and HLA-A*02 geno-
type was assessed by PCR. 
In the initial study of patients with primary CRC of stage II and III, a high HER3 expression 
was seen in 70% of tumors and in 75% of lymph node metastases. Tumor and lymph node 
metastases correlated according to HER3 expression. HER3 did turn out to be an independent 
prognostic factor and high expression was associated to decreased survival. FISH analysis of 
CRC tumors did not show gene amplification with respect to HER3 expression.  
A high expression of HER3 was seen in about 80% of primary CRC as well as in correspond-
ing lymph node and liver metastases. There was a correlation between HER3 expression in 
primary tumor and metastases. 
In the third study, high HER3 expression in colon cancer was associated to distal colon loca-
tion and low-grade tumor. In distal colon cancer, high HER3 expression was of negative 
prognostic value according to disease free survival (DFS).  
The results in our last study indicate that a combined analysis of HER3, MMR expression and 
HLA-A*02 genotype can have a prognostic value and can, to some extent, predict response to 
adjuvant 5-fluorouracil (5-FU) based chemotherapy in subgroups of primary colon cancer.  
Frida Lédel 
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A single molecular biomarker or a combination of markers may play a relevant prognostic 
and predictive role though CRC is a complex and heterogeneous disease. Subtyping of CRC 
based on molecular, clinical and morphological features includes biomarkers and is difficult 
however, necessary when planning optimal treatment for each individual patient.  
 
Key words: Colorectal cancer, colon cancer, HER3, IHC, lymph node metastases, liver me-
tastases, prognosis, tumor location, biomarker, differentiation, MMR, HLA-A*02, adjuvant 
chemotherapy 
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THESIS AT A GLANCE 
________________________________________________________________________ 
 
 
 
 Hypothesis Patients and methods Results Conclusion 
I 
 
The expression of 
HER3 in primary 
tumor of CRC is 
elevated and corre-
lates to expression in 
lymph node metasta-
ses. HER3 is associ-
ated to survival and 
prognosis. 
CRC, stage II and III, n=236, 
IHC, FISH 
 
 
70% of tumors had high 
HER3 expression and 75% 
of lymph node metastases.  
High HER3 expression was 
a negative prognostic factor. 
Correlation of HER3 ex-
pression between tumor and 
metastases was observed. 
No gene amplification exist-
ed. 
 
High HER3 was de-
tected in 70% of tu-
mors, in 75% of lymph 
node metastases and 
correlated mutually. 
High HER3 expression 
was prognostic and 
predicted a worse 
outcome. 
II 
 
The expression of 
HER3 in CRC, in 
lymph node and 
liver metastases is 
elevated and expres-
sion in tumor and 
metastases corre-
lates. 
Resected CRC + liver metasta-
ses, n=107, IHC 
 
 
80% of primary tumors had 
high HER3 expression, 81% 
in lymph node and 82% in 
liver metastases. Correlation 
in HER3 expression be-
tween tumor, lymph node 
and liver metastases was 
observed.  
 
High HER3 expression 
was seen in about 80% 
of CRC and corre-
sponding metastases. 
Correlation existed 
between HER3 expres-
sion in tumor and 
metastases. 
III 
 
The expression of 
HER3 in primary 
colon cancer is 
elevated. HER3 is 
associated to prog-
nosis and tumor 
location. 
Colon cancer, stage II and III, 
n=521, IHC 
 
High HER3 was expressed in 
67% of colon tumors. High 
HER3 expression was asso-
ciated with distal colon and 
low-grade tumor. In patients 
with distal tumor, high HER3 
expression correlated to 
shorter DFS. 
 
 
In this enlarged, refined 
study, high HER3 
expression in colon 
cancer was associated 
to distal colon and low-
grade tumor. High 
HER3 expression was 
of negative prognostic 
value in distal tumors. 
IV 
 
A combined analysis 
of biomarkers 
HER3, MMR and 
HLA-A*02 sharpens 
prognostic value in 
colon cancer. 
Colon cancer, stage II and III, 
n=493, IHC, PCR  
 
 
Correlation between high 
HER3 expression and profi-
cient MMR existed. When 
adjuvant therapy was given 
to high HER3/pMMR pat-
ients, a tendency to prolong 
DFS was seen compared to 
only surgery. In females 
with stage III, receiving 
surgery alone, the combina-
tions high HER3/HLA-A*02 
and proficient MMR/HLA-
A*02 had worse outcomes 
compared to not having 
HLA-A*02.  
A combined analysis of 
HER3, MMR and 
HLA-A*02 held prog-
nostic value and a 
tendency to prediction 
was observed regarding 
adjuvant chemotherapy 
in subgroups of pa-
tients.  
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INTRODUCTION 
___________________________________________________________________ 
 
Cancer in general 
The problem; suffering and dying people! 
Cancer is a leading cause of death worldwide, accounting for 8,2 million deaths of which 
694 000 constitutes of colon and rectal cancer (2012) [1].  
Causes, why cancer? 
Cancer arises from one single cell. It is a multistage process when a normal cell transforms 
into a tumor cell. These changes are the result of the interaction between one individual´s 
genetic factors and three categories of external agents; 
Physical (e.g. radiation)    Chemical (e.g. tobacco, food)    Biological (e.g. intestinal flora)                                                                                
Ageing is also fundamental for the development of cancer. The incidence of a specific cancer 
rises with age and that is due to a build-up of risks. Risk accumulation interacts with the cel-
lular repair mechanisms that become less effective as a person grows older. 
 
 
                            
                                      Figure 1. Ref; Hanahan and Weinberg 2011 
 
 
HLA-A*02  
HER3 
MMR 
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Risk, “big five” 
A large proportion, 30%, of cancer deaths could be prevented. Tobacco, alcohol, unhealthy 
diet, physical inactivity and some chronic viral infections (hepatitis B and C, HIV and HPV) 
are the “BIG FIVE” of the cancer safari. 
Reduce cancer risk, HER3? 
Through cancer prevention (the dream is to be able to use HER3 here), early detection (the 
dream is to also use HER3 here) and management of patients (we might have reasons to use 
HER3 here) the cancer risk can decrease. Maybe, I can contribute with this work to reduce 
the cancer burden. 
 
Colon and rectal cancer  
Colon and rectal cancer are diseases of welfare where the highest incidences are found in 
Europe, USA and Oceania. In Sweden, 6162 colorectal cancer (CRC) cases were diagnosed 
in 2013. CRC is the third most common cancer disease [2]. The age standardized mortality 
has decreased and overall survival has increased during the last 30 years [3]. The age specific 
incidence of CRC shows the same characteristic pattern for colon and rectal cancer, common 
in the elderly and unusual among the young [4]. Since both incidence and survival of CRC 
have increased during the last decades, the number of patients treated for the disease has 
grown. As for several other tumor forms, there is no single triggering factor known for CRC. 
Etiological factors can be carcinogens in feces and mutagens in Western food. The geograph-
ical variation of CRC incidences is scattered and can change within a generation when mov-
ing from a low risk to a high risk area. This might be explained by lifestyle or environmental 
factors like e.g. red meat, poor intake of fruit and vegetables, physical inactivity, obesity, 
tobacco and alcohol. Though the evidence for etiological factors are not so strong, a reduction 
of up to 30% of CRC have been estimated and could be prevented by change of food and 
lifestyle [5]. HLA genotypes differ in expression around the world in an evolutionary way 
and may also have an impact in CRC [6]. Other general features of CRC are that men have a 
slightly higher risk of getting adenomas as well as CRC and preferably distal colon and rectal 
tumors. Women tend to have an overweight of proximal tumors, especially at a higher age 
[3]. Diabetes, widespread, chronic ulcerative colitis and Crohn´s disease augment the risk of 
CRC [7, 5]. Age is the single most important risk factor followed by heredity for CRC in the 
clinic. 
 
Colon cancer 
The trend of incidence for colon cancer in Sweden is increasing over decades but in the last 5 
years, it is actually declining. Another trend is that fewer deaths of colon cancer are seen in 
   ……………….Introduction 
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the last 30 years (Figure 2). The 5-year survival rates for all stages of colon cancer were 65% 
for females and 62% for males in 2009 to 2013 [4].  
 
Numbers/year/100 000 persons; 
                                New cases                                                        Deaths 
 
Figure 2. Colon cancer 
Adapted from Nordcan 
 
Rectal cancer 
The trend of incidence for rectal cancer in Sweden is slightly increasing but flatter compared 
to colon cancer over decades. Like colon cancer, the trend is that fewer deaths of rectal cancer 
are seen in the last 30 years (Figure 3). The 5-year survival rate for all stages of rectal cancer 
is 66% for females and 62% for males from 2009 to 2013 [4]. 
 
Numbers/year/100 000 persons; 
                               New cases                                                         Deaths 
 
Figure 3. Rectal cancer 
Adapted from Nordcan 
Frida Lédel 
 
20 
Symptoms 
The majority of patients with CRC are asymptomatic. The symptoms can differ according 
to tumor location in proximal, distal or rectal cancer. Changed habits of defecation, blood 
or mucus in the stools, urgency, pain to defecate, abdominal pain (constant or intermittent), 
weight loss, anemia and abdominal swelling are all common symptoms. Large bowel ob-
struction which constitutes of 20% of the onset of all CRC, bleeding or tumor associated 
perforation are late symptoms [8].  
 
Prevention 
Colorectal tumors are suitable for screening in a biological point of view but optimal meth-
ods of investigation, which are easy to use, free of risk to patients, with a high sensitivity 
and specificity, are not fulfilled. As of today in literature, screening can probably result in 
increased survival in subgroups but might not affect the total CRC mortality [5, 8]. Screen-
ing gains in colorectal cancer with fecal occult blood detection and colonoscopy for patients 
at the age of 60 are investigated in Sweden in the SCREESCO trial [9]. 
 
Investigation  
To start the investigation with a colonoscopy and rectoscopy to get a biopsy and acquitting 
from synchronous tumors are gold standard in CRC. Computed tomography (CT) 
colography can be performed instead of colonoscopy but without the important biopsy op-
portunity. Further, CT is done of the thorax and abdomen for a radiological, preoperative 
staging of the tumor and to detect metastases. A rectal digital exam should be done in the 
clinical examination. For rectal cancer, magnetic resonance imaging (MRI) is always done 
because of the clear anatomical vision of the pelvic space [10]. Positron emission tomogra-
phy (PET-CT) is used to map a locally advanced, primary tumor or to evaluate if the meta-
static situation is curative or palliative. MRI or ultrasound with contrast of the liver can be 
of complement in the preoperative investigation or in the follow up surveillance and radio-
logical controls. Trans rectally performed ultrasound can be of complement to MRI. The 
tumor marker carcinoembryonic antigen (CEA) assessed from a blood sample, is used in 
clinical practice as a diagnostic tool as well as in the follow up of CRC to detect recurrenc-
es [11]. 
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Multidisciplinary team conference 
During the last decade, multidisciplinary team (MDT) conferences have been established in 
Sweden. These conferences are structured meetings with colorectal surgeons, oncologists, 
radiologists, pathologists and specialized nurses and when needed, liver and thoracic sur-
geons present. Each patient´s colorectal cancer case is individually discussed at least at two 
occasions, pre- and post-operative and again if a recurrence occurs. In a complicated case, 
the patient is discussed more frequent. Decisions concerning pre- and post-operative stag-
ing, treatment and follow up are made at the MDT. The aim of the conference is to tailor 
the optimal surgical and oncological treatment for each individual patient. Improved sur-
vival is a hard endpoint that is reached since implementation of MDT conferences [12]. 
Further systematic review of the MDT´s is needed. A panel of different biomarkers is be-
coming standard in MDT settings of other solid tumors e.g. breast cancer and lung cancer, 
which are of help when making each patients very best decision [13, 14]. In CRC, mi-
crosatellite instability (MSI) status and KRAS mutation of the tumor are sometimes com-
plemented at the MDT to determine if adjuvant chemotherapy or epidermal growth factor 
receptor inhibitor e.g. cetuximab are going to have effect. HER3 expression or HLA-A*02 
genotyping are not yet used in the clinic.     
 
Treatment 
Surgery 
Surgery is the primary treatment of CRC. Time between diagnosis and surgery should be 
minimized and no longer than 6 weeks. Curative resection of CRC is the strongest associat-
ed factor of survival of the patient [8]. The surgical techniques in CRC have changed step-
wise with e.g. the total mesorectal excision (TME) in rectal cancer, “high thigh” ligation of 
colonic vessels as proximal to the aorta as possible in all bowel resections and taking the 
complementary mesentery en bloc, harvesting as many lymph nodes as possible [15, 16, 17, 
18]. These improvements have all together prolonged survival. Morbidity and mortality 
related to surgery have decreased due to a more accurate pre-operative investigation, mod-
ern anesthetic and surgical techniques. Open, laparoscopic or robotic approaches of CRC 
surgery are used. Principles of operation of CRC are resection of the tumor affected bowel 
segment with an adequate marginal. Bowel resection is done en bloc with corresponding 
mesentery, containing lymph vessels and regional lymph nodes. Resectable, distal metasta-
ses (e.g. suspected malignant nodes of the para aorta, obturatorius foramen, groin or liv-
Frida Lédel 
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er/lung metastases) are taken away either at the operation of the primary tumor, before or 
after, regarding scenario. The entire abdominal cavity should always be examined for visi-
ble or palpable metastases [8]. Lymph node extirpation (regional and resectable, metastatic 
distal) is necessary for the TNM-staging of the tumor but can also have a therapeutic rele-
vance.  
 
The different resections of the colon and rectum for tumors are; right and left 
hemicolectomy (extended or not), transeversectomy, total and subtotal colectomy (synchro-
nous tumors, FAP or HNPCC), sigmoidectomy and rectal resection or amputation. Acute 
colon resections for colon cancer are done in 20% of all cases and should, if possible, be 
avoided [19]. An obstructing tumor is the most common cause but also perforation or 
bleeding can be reasons for acute surgery. Pre-operative, TNM-staging is strongly recom-
mended even if the setting is acute or semi acute. Acute colon cancer surgery is more de-
manding then elective and is often performed out of regular hours and without colorectal 
competence. For patients having acute resections of colon cancer, the prognosis is negative-
ly affected [19]. The procedure can be more extensive due to the condition of bowels com-
pared to elective surgery. Stoma of some kind is more common and often recommended in 
the acute setting [20].  Common complications of bowel surgery are leakage of the anasto-
mosis, infections (wound, abdominal abscesses, pneumonia, urinary tract) and rarely occur-
ring today, bleeding. 
 
Radiation 
Radiation has a direct tumor cell killing effect but can also sensitize cancer cells to be found 
by the immune response or recruit the immune response itself. Radiation is given to rectal 
cancer patients to reduce the risk of local recurrence [21]. If radiation has an effect, the tumor 
visibly shrinks and/or fibrosis transformation of the tumor is seen on MRI or in the pathology 
report. Preoperative given radiation according to standard (5x5 Gray) of rectal cancer has 
decreased the local recurrence rates [8]. The border between resectable and unresectable tu-
mor is not razor sharp. The MRI can present three different tumors; favourable “good” group, 
intermediate “bad” group and advanced “ugly” group [22]. Many studies have been conduct-
ed on how and to whom to give radiation (optimal dose, administrative pattern, tumor type) 
and if it should be combined with chemotherapy [23, 24]. The category of “good” does not 
need radiation. The second category, “bad”, constitutes the largest group of patients and the 
risk of local recurrence is higher than the expected morbidity of radiation itself so standard 
radiation is recommended. In the category of “ugly”, radiation and neo adjuvant chemothera-
   ……………….Introduction 
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py is definitely needed to get a radical resection, to prevent local recurrence and in some cas-
es to obtain shrinkage and convert an inoperable tumor to an operable case [25, 26]. Radia-
tion can cause a complete response in some patients, which means that the tumor is no longer 
radiologically or pathologically detected [27]. MRI staging is the superior modality for 
choosing the right patients that need radiation but the tumor tissue biopsy also matters. Local 
recurrence risk has decreased because of better surgery and radiation but survival has not 
significantly improved yet. RAPIDO is an ongoing, randomized, multicenter study where 
patients of high risk of recurrence are included [28]. The hypothesis is that chemotherapy 
combined with radiation in rectal cancer can add in systemic effect and increase tumor con-
trol locally, which might result in increased survival in advanced tumors. Radiation of colon 
cancer is not usually performed because of the non-fixed position of bowel tumor and simul-
taneously risk of damage to the small bowels, which are sensitive to radiation. However, ra-
diation of long term and high dose can be considered in locally advanced colon cancer cases 
without metastases combined with chemotherapy [29]. 
 
Adjuvant chemotherapy 
The hard endpoint of systemic adjuvant chemotherapy in resected CRC patients is to eradi-
cate the micro metastases that might exist [30]. While the pre-operative staging has improved, 
surgery and pathology have as well, thus resulting in stage migration. This means that the 
stage specific recurrence risk and stage survival have changed but not in total. This is known 
as the Will-Rogers phenomena [31]. 5-Fluorouracil (5-FU) based chemotherapy is standard 
adjuvant treatment for stage III colon cancer [32, 33]. Adjuvant 5-FU and e.g. calcium 
folinate (potentiates 5-FU) started within 8 weeks of surgery and given for 6 months to pa-
tients <76, can reduce risk of recurrence with 30-40%. The 5-year survival increases about 
10% [24, 32, 34]. Capecitabine (fluoropyrimidine), is an orally administrated prodrug of 5-
FU and is an equivalent to intravenous 5-FU and calcium folinate [35]. The enzyme 
thymidylate synthase (TS) and DNA synthesis are inhibited by 5-FU. Leucovorin, calcium 
folinate and other similar agents stabilizes the binding of 5-FU metabolite, 
fluorodeoxyuridine monophosphate to nucleotide-binding site of TS, forming a ternary com-
plex [33, 36].  
Supplementary treatment to 5-FU is given to patients with high-risk tumors that can tolerate 
it. Oxaliplatin is an inhibitor of DNA replication, inhibiting topoisomerase that blocks DNA 
repair and is a down-regulator of TS [37]. Neuropathy is the main side effect of oxaliplatin 
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that can be permanent. Patients older than 70 years old probably have more side effects than 
gains of oxaliplatin but can tolerate 5-FU though biological age should be considered [38]. 
Both cetuximab and irinotecan are used in the metastatic CRC setting. For a simple overview 
see Table 1 below. 
 
Table 1. Overview of CRC and oncological treatment. 
 
More documented research exists in the colon cancer and adjuvant chemotherapy field com-
pared to rectal cancer. Studies are now conducted for rectal cancer but the evidence base is 
still not completely solid. In general, colon and rectal cancer patients of stage II are not given 
adjuvant chemotherapy and colon cancer of stage III do get chemotherapy. Selected rectal 
cancer patients of stage III get adjuvant chemotherapy. The stage specific risk of recurrence 
or death, not regarding treatment, can be seen in Table 2.  
Stage Risk of recurrence or death in 3-5 years 
 
II (20-30%) 20-40% 
III (30-40%) 40-60% 
IV (20%) ~85% 
Table 2. Risk and stage in CRC. 
 
Stage II patients with colon cancer at risk with e.g. high-grade tumor, tumor vessel growth, 
T4 or few harvested lymph nodes, tumor perforation and relative low age are all parameters 
that often render in an adjuvant chemotherapy decision. If tumor perforation exists, the risk 
for recurrence is high which motivates adjuvant chemotherapy. Colon and rectal cancer pa-
tients of stage III get adjuvant chemotherapy with a believed beneficial effect of 10-20% [32].  
Oral capecitabine or intravenous 5-FU+calcium folinate with or without oxaliplatin do have a 
proven effect but is to a high extent dependent on risk factors, patient and tumor characteris-
tics [39]. It is clinically relevant to even more specifically identify stage II and III patients 
that we know would or would not benefit from adjuvant chemotherapy. If guidelines of CRC 
Adjuvant treatment Additional adjuvans  Metastatic treatment 
 
5-FU/calcium folinate  
or leucovorin 
 
Oxaliplatin  5-FU/calcium folinate  
or leucovorin 
Capecitabine  Capecitabine 
  
Oxaliplatin 
  
Irinotecan 
  
Cetuximab 
Bevacizumab 
Panitumumab 
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and adjuvant chemotherapy from the Swedish National Board of Health and Welfare are fol-
lowed, recurrence or premature deaths are estimated to be prevented in 2-4/100 patients [3, 
8]. The use of biological agents like cetuximab, panitumumab, bevacizumab and others have 
an effect in metastatic CRC (mCRC) but not yet a proven effect as neo adjuvant or adjuvant 
treatment. The ways to administrate chemotherapy are orally or intravenously. 
 
Colon cancer and chemotherapy 
5-FU has been given as adjuvant chemotherapy in colon cancer for many decades. The addi-
tive effect of 5-FU to surgery is favorable in about 7% in colon cancer of stage II and III [32, 
33]. A study from the nineties [36] and following studies still hold strong and patients with 
colon cancer stage III receive adjuvant chemotherapy today. The side effects are tolerable and 
only a few late side effects are seen of chemotherapy [33]. If oxaliplatin is given additionally 
to 5-FU/calcium folinate or capecitabine to patients with colon cancer stage III, the relative 
risk of recurrence decreases another 20%. In stage II it is still not completely clear if the gains 
of oxaliplatin are as large as in stage III [40, 41]. 
 
Rectal cancer and chemotherapy 
Increased survival of the combination of radiation and neo adjuvant or adjuvant chemothera-
py has been hard to prove in rectal cancer [24, 42]. Results from large scale colon cancer tri-
als have been extrapolated to give adjuvant chemotherapy to rectal cancer patients of stage III 
and patients at risk in stage II. In non-radiated and radiated patients with tumors presenting a 
high grade of risk factors, oxaliplatin can be given additionally to adjuvant chemotherapy. 
Since TME surgery and radiation have been combined, the loco regional problem in rectal 
cancer is almost eliminated [43]. Neo adjuvant radiochemotherapy in rectal cancer patients is 
shown to improve local control in the advanced, “ugly”, group of tumors, but does not im-
prove survival [21, 44]. The gain of adjuvant chemotherapy after neo adjuvant chemotherapy 
is unknown. If a tumor is down staged by radiation and chemotherapy, the gain of adjuvant 
chemotherapy is probably low [43, 45].  
 
CRC, metastases and chemotherapy 
CRC with limited liver and/or lung metastases can be operated with a curative intention 
more than once. If these patients are selected in a proper way, a 5-year survival of 45-50% 
is observed compared to all stage IV patients where the 5-year survival is much lower [46]. 
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Neo adjuvant, adjuvant or peri-operative chemotherapy have been given in these cases after 
a MDT decision [47, 48]. The resection of CRC and liver metastases can be done synchro-
nous or at two occasions depending on the level of difficulty. The EPOC study has shown 
that a sandwich model of peri-operative administration of chemotherapy, FOLFOX (5-
FU+calcium folinate+oxaliplatin) and cetuximab prolongs DFS [47]. CRC and lung metas-
tases are operated at two occasions.  
 
Biological therapies 
As an additional treatment to chemotherapy, four antibodies are used which are tyrosine 
kinase inhibitors (TKI); bevacizumab (VEGF inhibitor), cetuximab and panitumumab 
(EGFR inhibitors) and regorafenib (multitarget inhibitor). These new drugs have a well 
documented but restricted effect and are expensive. Cetuximab and panitumumab can be 
given without the combination of cytostatics in mCRC and give a remission of 10% in un-
selected patients. RAS wildtype (KRAS and NRAS) in the tumor is a requirement for the 
EGFR inhibitors to work and raises remission with 20-30% [49, 50]. The two drugs are 
similar in the third line of mCRC in a randomized study [51]. Irinotecan can be combined 
with e.g. cetuximab and render patients an improved survival [52]. Other prognostic mark-
ers like HER3 expression can interact with TKI´s. 
 
Heredity 
Familial syndromes are estimated to cause 25% of CRC but only 5% have an identified 
genetic defect [53]. Risk of hereditary cancer is when an individual has inherited a mutated 
gene that makes the person more prone to developing cancer. There are families where sev-
eral members will develop colon or rectal cancer. In such families, cancer occurs more of-
ten than would have been expected by chance yet is not detectable hereditary. Little is 
known about the causes of cancer in these families [53]. Epigenetic interactions might oc-
cur between genes or gene clusters and the environment. This type of moderately increased 
cancer risk is named "familial colon and rectal cancer." Genetic testing for hereditary CRC 
can be done from a blood sample.  
 
Hereditary nonpolyposis colorectal cancer (HNPCC) 
HNPCC, also known as Lynch syndrome, is the most common form of hereditary colon 
cancer, accounting for ~3% of all colorectal cancer each year [54]. It should be suspected 
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when CRC is diagnosed at a low age or heredity is present. Although not each and everyone 
with HNPCC will develop colorectal cancer, the risk is greatly increased compared with the 
general population. The CRC risk is approximately 80% over a lifetime. In HNPCC pa-
tients, colonoscopy with polypectomi when needed, each 1-2 years should be performed, 
starting at 20-25 years of age. This procedure lowers the risk of CRC and extends expected 
survival [55]. The risk of developing other cancers in e.g. the endometrium, ovaries or pros-
tate is increased in HNPCC. The genes that have been associated with HNPCC are inherited 
germline mutations in DNA mismatch repair (MMR) genes (MLH-1, MSH-2, MSH-6 
and PMS-2) (Figure 10) [56]. The consecutive effect is widespread microsatellite instability 
(MSI).  
 
Familial adenomatous polyposis (FAP) 
FAP is a rare hereditary condition in which the patient has hundreds to thousands of polyps 
in the colon and rectum. FAP accounts for approximately ~1% of all colorectal cancer each 
year [57]. The polyps are adenomas and not cancer. However, they have the potential to 
develop into cancer. The polyps begin to occur in teenage years and malignification is 
complicated to monitor. Colonoscopy is recommended annually from 12 years of age until 
total colectomy [58]. The majority of tumors develop in the distal colon and rectum. If the 
colon of a person with FAP is not removed, eventually CRC will be developed. FAP pa-
tients can also develop polyps in other gastrointestinal (GI) locations and there is an in-
creased risk of GI cancers, desmoids, thyroid cancers and medulloblastoma. Non-cancerous 
features of FAP include soft tissue tumors like osteomas, skin cysts, dental abnormalities 
and congenital hypertrophia of the retinal pigment [59]. The gene associated with FAP 
is germline mutated APC that is an early and crucial step in the adenoma carcinoma se-
quence. Patients with FAP have a mutation in the APC gene, which can be inherited (Figure 
7) [60].  
MYH-gene associated polyposis (MAP) is another inherited, rare form which develops later 
in life than FAP. People with MAP and FAP have very similar polyp development and the 
only way to distinguish between the syndromes is with genetic testing [60].  
Other forms of hereditary colon cancers are; depending on chromosomal location or single 
nucleotide polymorphism (SNP´s). Juvenile Polyposis, Peutz-Jegher’s syndrome and PTEN 
hamartomas have a greater risk for CRC [53]. 
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Embryology and Tumor location  
Epidermal growth factors mediate their effect on epithelial cells in the colon and rectum 
through binding to naturally located epidermal growth factor receptors at the basolateral 
site of the cell membrane. The epidermal growth factor receptors play a major role in em-
bryonic development, morphogenesis and maintenance of the colonic and rectal epithelium 
as well as in oncogenesis [61]. Survival, migration and mitosis of stem cells and pre-
differentiated cells resulting in mature epithelial cells are regulated by the epidermal growth 
factor receptor (Figure 4).  
 
 
 
 
 
 
 
 
 
Figure 4. Proliferation, migration and differen-
tiation from stem cells to epithelial cells in the 
submucosal bowel crypts  
Adapted from Nature Reviews Cancer 
 
In CRC, this order of proliferation and differentiation of cells is changed and epidermal 
growth factor receptors are over expressed in an abnormal, distributional pattern in the 
complete cell membrane [62]. In all epithelial cell types, epidermal growth factor receptors 
exist which illustrate their modulatory functions on various differentiated cells of the colon 
crypt [62]. In a fetus, epidermal growth factor receptors increase in number during gestation 
and at the same time, ligand affinity decreases but in cancer this autonomal control is lost 
[63]. Epidermal growth factor receptors EGFR, HER2, HER3 and HER4 are important tar-
gets for clinical applications in cancer detection and therapy because they regulate prolifer-
ation, invasion, angiogenesis and metastases of cancer cells [63]. The location of tumors 
related to expression of epidermal growth factor receptors have been studied (Figure 5). 
EGFR, HER2 as well as HER3 are over expressed throughout the colon but at a higher ex-
tent in distal colon and rectal tumors compared to proximal tumors [64, 65]. 
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Figure 5. Tumor location related to phenotype and genetic background. 
Adapted from Nature Reviews Cancer 
 
One distinctive embryonic feature is the rudiment of midgut and hindgut resulting in prox-
imal and distal colon. The caecum, ascending and 2/3 of the transverse colon derive from 
the midgut while the colonic segment including splenic flexure, left colon, sigmoid and 
rectum, derive from the hindgut. The dual blood supply of the colon reflects the different 
embryonic origins. Regarding innervation of the colon and rectum, it´s divided, where 
proximal colon is supplied by the vagus nerve, while the distal colon and rectum are main-
tained from the S2, S3 and S4 [66]. The distinction between the colon and rectum is ana-
tomical but surgical and radiotherapeutic management differs. Tumor location is potential 
with prognostic and predictive implications [67, 68]. 
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Staging 
Diagnostic information in the pathology report is based on the macro as well as the micro-
scopic tissue analysis of a CRC tumor and is decisive for endoscopic or surgical removal and 
for neo adjuvant or adjuvant treatment [69]. It additionally gives feedback to the MDT on the 
radiological tumor, node, metastases (TNM) staging, quality of surgery and results of onco-
logical treatment. The pathologist is recommended to use the latest WHO Classification of 
Tumors of Digestive System 2010, as of date, the 7th edition of UICC, TNM Classification of 
Malignant Tumors [70].  
T is how deep in the bowel wall the tumor is infiltrating. N gives information on the number 
of regional lymph node metastases. M is if distant metastases exist. Stages 0 to IV are used 
(Table 3).  
 
Table 3. TNM and stage. 
As an addition to TNM, certain validated risk factors are used to predict recurrence and me-
tastases (Table 4) [70]. 
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Risk factors of recurrence and metastases in CRC 
 
T4, N1-2, M 
Number of analyzed lymph nodes <12  
High grade tumor 
Vascular invasion 
Lymphatic invasion 
Perineural tumor growth 
Tumor deposits 
Tumor budding 
Infiltrating tumor border 
Tumor perforation 
 
Table 4. Pathological risk factors of CRC. 
 
Pathology 
According to the simplified paradigm of a CRC tumor, cancer arises from an adenoma esti-
mated to take many years to malignify (Figure 6) [71].  
 
 
Figure 6. Growth of tumor in the bowel wall and stages of CRC. 
Adapted from National Cancer Institute 
Surgical resection is the most effective treatment of CRC. Histopathological examination of 
the tumor specimen according to the TNM system can predict prognosis. The depth of tumor 
infiltration in T3 tumors is related to prognosis and is independent of stage. T4 tumors can 
break through the serous surface and have a worse prognosis compared to being spread to 
adjacent organs [72]. Dukes staging system (A-D) is today replaced by the 0-IV staging sys-
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tem. The number of analyzed lymph nodes is of importance for correct staging and an indica-
tor of surgical and pathology quality and the ruling ground for adjuvant chemotherapy deci-
sion [72]. If more than 12 negative regional lymph nodes are found, this is predictive of stage 
I or II [73]. Low-grade cancer is defined to have ≥50% glandular formations and are well to 
moderately differentiated while high-grade cancer has ≤50% glandular formations and are 
low differentiated [72]. Tumor budding is a single cell up to a small cluster of undifferentiat-
ed, stemlike cells adjacent to the tumor. It is suggested as the first event of migration of can-
cer cells and is a negative prognostic factor [74]. Tumor deposits are larger clusters of tumor 
cells which are a kind of micro metastases. These are often seen close to the tumor as well 
[75]. Two types of tumor borders are identified, pushing or infiltrating where the latter is as-
sociated to recurrence risk and metastases [74].  
The surgeons are recommended to adequately mark important anatomical structures and send 
the specimen fresh or in formalin to the pathology department. A minimizing of autolysis 
should be pursued. A tumor is after resection, conserved through formalin fixation and paraf-
fin embedded (FFPE). Sliced FFPE tumor sections (3-5µm) are fixed on glass slides and mul-
tiple analyses can then be done, including IHC. From tumor tissue, one can extract DNA 
from fresh but also from fresh-frozen or formalin-fixed paraffin embedded tumor. Quality of 
DNA and DNA degradation are depending on the e.g. dilution of formalin solution, time to 
fixation and fixation time. DNA can be used for various types of molecular genetic analyses. 
Tissue micro array techniques are micro biopsies from the same or different paraffin embed-
ded tumors that are analyzed at the same time with immunohistochemistry (IHC) or fluores-
cence in situ hybridization (FISH). This is a time and tissue sparing method which enables 
multiple biomarker analyses in a number of tumors. For clinical practice in CRC, we are not 
there yet. Today only MSI-testing and KRAS (PCR) are reliable, validated biomarkers. 
Biobanks of CRC tumors are now established for clinical trials and for individual hospitals. 
This is going to be of great importance for future research possibilities regarding prognostic 
refinement and for identifying predictive factors of treatment. All biobanking need informed 
patient consent, ethical committee approval and a report to the National Board of Health and 
Welfare Registry of Biobanks. 
 
Inflammation and Immune response 
Long lasting inflammatory activity, e.g. ulcerative colitis, predisposes for CRC and in a life-
time, 18% of malignancies occur [76]. A combination of colitis, having risk factors of CRC 
and heredity can have a large effect on incidence and prognosis. Aberrant activities of 
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JAK/STAT signaling pathways have been implicated in the development and spread of vari-
ous cancer entities, among them CRC [77]. An equilibrium exists between immune response 
and CRC where the JAK/STAT pathway has an impact. The JAK/STAT complex is present 
in e.g. lymphocytes and is activated by interferons, interleukins, cytokines and growth fac-
tors. STAT1 and 3 expression and activity constitute as independent favorable prognostic 
markers for CRC, where STAT protects the individual from cancer [77].   
MSI tumors also present this balance between the immune system fighting the tumor while 
the tumor is trying to evade immune response [78]. Genetic MMR deficiency results in MSI 
tumors and represents a specific phenotype in CRC. Epigenetic silencing of DNA mismatch 
repair and hypoxia have been shown to affect inflammatory bowel disease-associated CRC 
[79]. Elevated microsatellite alterations at selected tetranucleotide repeats called EMAST is a 
commonly presented form of MSI that is initiated by inflammation and modulates CRC pro-
gression [80]. 
The HLA-A*02 genotype might have an impact on prognosis since it is associated to ovarian 
tumors and colon tumors of advanced stages and to a worse prognosis [81, (Villabona et al. 
“Analysis of immune-related prognostic markers in colon cancer in patients randomized to 
surgery or surgery and adjuvant cytostatic treatment”, submitted 2015)]. One hypothesis be-
hind this is that the HLA-A*02 genotype impairs immune response in CRC.  
The HER complex is present in all epithelial cells in a normal state and in an aberrant pattern 
in CRC. Very little is known of HER3´s over expression in CRC and its relationship to im-
mune response. What is evident though is that when inhibiting antibody treatment like 
cetuximab is given, acquired resistance occurs and HER3 might have an impact [82].  
Information on HER3 expression in sporadic colon tumors and how it interacts with MMR 
and HLA-A*02 genotype is sparse. Different HER complex members can be targets for 
CTL´s in cancer cells. HER complex expression has been reported to associate to MHC class 
I. Over expression of HER complex might impair CTL mediated recognition of HLA-A*02 
restricted tumor antigens [83, 84].   
 
Metastases in CRC 
The definition of metastases is the presence of tumor growth, away from the tumor, in distant 
lymph nodes or in other organs, documented by radiology, pathology or clinical examination. 
The survival is poor in CRC of stage IV (Table 2) [85]. The most common locals of CRC 
metastases are in the liver, the lung, para aortal lymph nodes and other distal lymph nodes 
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[86]. Among CRC patients, 15-20% have liver metastases at diagnosis, another 20% metasta-
size metachronously [87]. Even if CRC is spread to the liver, it is potentially curable with 
surgery in 20% of all patients and it has markedly increased survival [87]. When investigating 
tumor biology of synchronous and metachronous colorectal liver metastases and molecular 
marker expression, it is concluded that most genetic aberrations in the primary tumor are 
maintained in the CRC liver metastases [88]. Synchronicity might imply a more aggressive 
disease though biological differences between primaries of synchronous and metachronous 
groups have been difficult to prove [89]. KRAS mutational status, which is important when 
considering anti EGFR therapy, is maintained in primary CRC and in corresponding metasta-
ses [90]. In metastatic CRC treated with EGFR inhibitors while having high HER3 expres-
sion, patients had a worse outcome compared with a low HER3 expressing tumor [91]. This 
implicates again that HER3 might interact with the response and with acquired resistance to 
anti-EGFR therapy in cancer [92]. A gene expression signature of the CRC metastases has 
been suggested and a high expression of these genes in the primary tumor correlated with 
worse outcome [93]. 
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Genetic and epigenetic development in CRC 
Adenoma Carcinoma Sequence 
Adenomas are the most important lesions for carcinoma development as well as the sub-
group of hyperplastic polyps. It is a continuous progression from normal epithelium to ab-
errant crypt foci, to adenoma, to cancer and finally, to metastases. Approximately 10% of 
adenomas progress to CRC and it takes about 10-15 years [94]. With rising age, about 50% 
of the population has one or more adenomas in the colon. The size of the adenoma is asso-
ciated to high-grade dysplasia [95]. The adenoma carcinoma sequence proposes that specif-
ic mutations appear chronologically when a normal cell transforms to a carcinoma with a 
potential of metastatic behavior (Figure 7).  
 
 
Figure 7. Markers of oncogenetic events can be seen in purple boxes and phenotypes in red box-
es. 
Modified from Nature Reviews Cancer 
These mutations can affect genes and pathways that regulate differentiation and growth [96]. 
Mutated proto-oncogenes cause “gain of function”, which means uninhibited proliferation 
even in the absence of growth signals. Tumor suppressor genes handle “loss of function” in 
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the cell cycle and when these genes are silenced or mutated, the normal regulation and bal-
ance between proliferation and apoptosis is disturbed. 
The APC gene mutation, found in ~80% of CRC, is considered the initial event when a cell 
transforms into an adenoma [94]. The APC mutation is called the “gate keeper” of CRC. 
When the WNT pathway is active it increases proliferation in a cell and this is an early 
event in the adenoma carcinoma sequence. When APC is mutated, the WNT pathway is on 
nonstop and the cell proliferates [97]. A similar mechanism as for WNT is observed for 
mutated oncogene KRAS, seen in ~40% of CRC. KRAS is active between early and late 
adenoma transformation. KRAS is located at chromosome 12 and associated with growth of 
the adenoma through regulation of multiple functions in different pathways [98]. Mutated 
BRAF is another proto-oncogene that affects the sequence in early malignant evolution and 
interacts with the MAPK pathway. BRAF mutation is less frequent (<10%) than KRAS in 
CRC [99]. The cell proliferation rate will increase with KRAS and BRAF mutations. 
SMAD4 and TGFβR2 mutations also contribute in the malignifying process in CRC. 
TGFβR2 is considered a driver of MSI [98]. Late events in the sequence are mutated tumor 
suppressor gene, TP53, “the guardian of the genome” (>50% of CRC) as well as impair-
ment of the whole TGFβ pathway and loss of chromosome 18q (includes SMAD 2 and 4) 
[98].  
An alternative pathway from Fearon and Vogelsteins in CRC is observed for hyperplastic 
polyps where mutated BRAF starts the process and epigenetic events like promotor methyl-
ation and gene silencing keep it going [100]. MSI tumors arise through a methylated or 
mutated MLH-1 gene or others. Hyperplastic polyps leading to CpG island methylation 
phenotype (CIMP) and MSI tumors are more frequently seen in proximal colon [101, 102]. 
 
The MSI, CIMP and CIN phenotypes 
Parallel to the adenoma carcinoma sequence, there are three groups that are both independ-
ent and mutually overlapping (Figure 7).  
For solid tumors, chromosomal aberrations like aneuploidy or polyploidy are of im-
portance. In CRC, about 85% of the tumors follow the adenoma carcinoma sequence and 
present numerical chromosomal alterations called chromosomal instability (CIN) [98]. In 
CIN tumors, chromosomal composition drives recurrent gains and losses that affect chro-
mosomes in a non-random manner. The cause of CIN is not known, but it is suggested that 
alterations in the mechanism apparatus when chromosomes segregate in mitosis might be a 
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cause. CIN tumors are distally located, of low-grade, more often have malignant nodes and 
metastases and do not have peri-tumoral lymphocytic infiltrate when compared to MSI tu-
mors. Associated mutated genes in CIN tumors are APC, KRAS and PI3K (Figure 7) [98]. 
Tumors in which microsatellite mutations are demonstrated are called microsatellite instable 
(MSI) and exist in 15% in sporadic CRC but also in HNPCC [102]. The MSI phenotype (de-
scribed in page 42) has defects in the mismatch machinery where errors that are introduced 
during replication, are left unrepaired [102]. At least four genes are involved in dMMR in 
humans MLH-1, MSH-2, PMS-2 and MSH-6 (Figure 10) [56]. Deficient MMR genes can 
cause MSI due to either mutations or hyper methylation of promotors that silence MMR 
genes. The order of succession is that dMMR in sporadic cancer occurs after mutations of 
APC and KRAS followed by a cascade of oncogenetic mutations (Figure 7) [103].  
The methylation described above is an epigenetic chemical modification of DNA folding that 
leads to gene expression changes called CIMP [103]. Sporadic biallelic silencing of e.g. the 
MLH-1 gene is a form of CIMP. Many genes have promoters embedded in clusters of cyto-
sine-guanosine residues, CpG islands. The CIMP phenotype resembles the MSI phenotype 
but is BRAF mutated, absent of MLH-1 and PMS-2 proteins through methylated silencing of 
the MLH-1 gene and is diploid. The cause of CIMP is also unknown [103]. Both MSI and 
CIMP are consequences of a defect MMR system but through different mechanisms. When 
using IHC, which measures protein expression, both causes are covered. The CIN and MSI 
phenotype initially were considered mutually exclusive but now are found to partly overlap. 
The CIMP and MSI phenotype are also overlapping to a large extent [102, 103] 
 
 
 
 
 
 
 
 
 
Frida Lédel 
 
38 
Biomarkers in CRC  
The definition of a biomarker is a biological factor that can be of various sorts; peptide, re-
ceptor, gene, allele or combinations that are used for risk prediction, as a diagnostic tool, for 
prognosis or prediction of treatment outcome [104]. 
The growing knowledge about molecular mechanisms of cancer in general has augmented 
expectations that compounds and abberations associated to oncogenesis can be used as bi-
omarkers. In a typical CRC, about 80 genes are mutated whence only a small fraction is 
found in the majority of patients and most mutated genes are present at low frequencies. 
Therefore, a wider perspective then genetics is needed [105, 106]. Below is a table of bi-
omarkers in CRC; 
 
Type of biomarker Use Biomarker 
 Risk Assess cancer development e.g APC, SMAD4, MSH, MLH1, MSH6, PMS2, 
PTEN and others 
Screening Cancer detection in asymp-
tomatic population 
Blood test, stool test (fecal hemoglobin) 
Diagnosis Detect presence of cancer miRNAs, coloscopic mucosal staining 
Classification Phenotype stratification MSI, CIN, CIMP 
Prognosis Outcome not related to 
therapy 
MSI,miRNA,Coloprint,Oncotype DX and others 
Prediction Predict response to therapy EGFR, KRAS, BRAF, PTEN, TP53, miRNA, 
MMR, HER3? HLA-A*02? Panel? 
Table 5. CRC biomarkers in different areas. 
 
Many biomarkers have been suggested but so far only KRAS and MSI are used as predictive 
biomarkers for the decision of therapy. 
In recent years, complete cancer genomes, trascriptomes and exomes have been sequenced 
[106]. Epigenetic mechanisms like DNA methylation profiles have been used for CRC sub-
grouping and miRNA have been showed to play a role in CRC [106, 107, 108]. Development 
of the molecular techniques and target oriented research have increased understanding of the 
human genome and its complexity as well as cancer specific aberrations. Micro RNA´s are 
short RNA´s that bind to complementary mRNA molecules, hindering translation to protein. 
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The non-protein coding transcripts of DNA where miRNA (which modulates cellular pro-
cesses) originate from have been conserved throughout evolution [107]. Micro RNA´s circu-
late in the blood and certain types of miRNA and changes in levels have been associated with 
tumor burden and cancer progression [108]. Comparing tumor exomes in individual patients 
can now identify cancer-driving mutations and sequencing differences between tumor and 
metastases providing information about genes important for the metastatic process [106]. 
 
Stage II, III and biomarkers  
Meta analyses have clearly shown a better prognosis of MSI colorectal cancers compared to 
CIN [109]. The outcome of patients with CRC of stage II and III disease is difficult to pre-
dict. Over expression, amplification and mutated HER complex members that signals through 
the MAPK and PI3K pathways are common in colorectal cancer and therefore a good target 
of treatment. EGFR inhibiting drugs are therapeutic alternatives to chemotherapy in mCRC. 
However, when KRAS is mutated and constantly active as well as the MAPK pathway, down-
stream of EGFR, this will result in failure of EGFR inhibition. Further, only 30% of the wild-
type KRAS patients will respond to EGFR inhibition. This indicates that there are other up-
stream or downstream effectors involved. A panel of predictive markers for stratifying treat-
ment decision might be a way to proceed. Also individual tumor sequencing is interesting as 
well as an individual comparison of healthy genome to tumor genome [105]. In the future 
clinical setting, these parameters can be examined further as a step forward in personalized 
prognostics and prediction in CRC of stage II and III.   
  
HER3          
The human epidermal growth factor receptor type 3 (HER3 or human ErbB3) is a 
transmembranous tyrosine kinase receptor belonging to the HER complex. HER3 is em-
bedded in the plasma membrane of the cell and neuregulins are its extracellular ligands. 
This receptor regulates cellular proliferation, differentiation, apoptosis and migration during 
embryogenesis and oncogenesis. The HER complex consists of four members, 
EGFR/HER1/ErbB1, HER2/ErbB2, HER3/ErbB3 and HER4/ErbB4 [110]. When a ligand 
binds, receptor dimerization takes place. While EGFR, HER3 and HER4 are activated by 
extracellular ligands, HER2 is an orphan receptor and is nonstop active [110]. The HER 
complex can be normally expressed, over expressed in an embryological manner and gene 
amplified or over expressed in cancer. A connection between the HER complex and the 
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WNT pathway might exist [111]. A challenge in imaging of HER3 is a quite low receptor 
expression in tumors, usually below 50,000 receptors per cell, together with significant 
HER3 expression in normal tissues [112]. Dysregulation of the HER complex is associated 
with a histological, malignant phenotype in CRC where the normal basolateral expression 
transforms to over expression in the complete cell membrane [113]. Receptors of the HER 
complex have an extracellular domain, an intracellular tyrosine kinase domain, which acti-
vate downstream signaling pathways, and an intracellular C-terminal tail (Figure 8).  
                                        
Figure 8. Protein structure of HER3. 
Adapted from Wikiprofessional 
However, HER3 has an inactive intracellular tyrosine kinase domain and its activation de-
pends on the heterodimer formation with other HER complex members, preferably HER2 
[114]. The HER2-HER3 unit activates downstream signaling pathways, such as P13K/AKT 
and RAS/MAPK and is considered as one of the most potent heterodimers in 
tumorigenesis(Figure 9) [115].  
 
Figure 9. HER3 expression, dimerization and function. 
Adapted from Nature Reviews Cancer 
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Evidence exists on the involvement of HER3 in various cancers, such as breast, prostate 
and colorectal cancer and its role in resistance to tyrosine kinase inhibiting (TKI) therapies 
[116]. The HER3 receptor is over expressed in about 70% of colon tumors [117, 118, 119]. 
Signaling can be affected by interdependency in between the HER complex (cross talk) 
[110]. For example, in response to trastuzumab (HER2 inhibitor) in HER2 over expressing 
breast cancer, HER3 can become up regulated and increase the signaling ability of HER2 as 
a compensation for its inhibition, which causes resistance to therapy [120]. It is also demon-
strated that autocrine activation of HER2 with heregulin occurs through dimerization with 
HER3 in colon cancer [121]. 
The importance of HER3 in several cancers points to its potential as a molecular target in 
anti-cancer therapy. This has stimulated the development of appropriate pharmaceuticals 
[122, 123]. Currently, several HER3-targeting monoclonal antibodies are evaluated in clini-
cal trials. To make anti-HER3 therapy effective, patients with HER3 over expressing tu-
mors have to be identified.  
Regarding the prognostic value of HER3 expression in colon cancer, the significance is not 
completely evaluated. Several reports have shown that HER3 expression is a prognostic 
factor in colorectal cancer (CRC) and might be of predictive value when cetuximab is given 
[124]. HER3 is found to be over expressed in primary colon cancer, rectal cancer, lymph 
node, liver metastases and it holds a certain prognostic value [117, 119, 125]. Studies indi-
cate that the HER complex is a promising target for immunotherapeutic interventions with 
antibodies (TKI´s) and T-cells based approaches [124, 126].  
 
MMR 
Microsatellite instability (MSI) is an epigenetic or genetic instability found in sporadic colon 
and rectal cancer.  Deficient MMR is a type of MSI where DNA errors are not repaired which 
result in a non-functional protein and in genomic instability. The deficiency or proficiency of 
MMR reflects the mechanism while MSI is the effect. Microsatellites are repeated units, one 
to six nucleotides long, usually located in non-coding regions and scattered throughout the 
genome and these sequences more frequently get errors. Deficient MMR tumors gain or lose 
repeat units at a higher frequency than in normal epithelial cells in the colon and rectum. 
Widespread MSI usually indicates mismatch repair deficiency (dMMR) [109]. The MMR 
genes maintain the stability and integrity of the genome. Inactivation of these genes promotes 
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accumulation at high speed of tumoral mutations. MMR genes are MLH-1, MSH-2, MSH-6 
and PMS-2 (Figure 10) [127].  
 
 
 
 
 
Figure 10. MMR, genetic function and in-
volved genes. Adapted from Nature Reviews 
Cancer                                                        
Deficient MMR and MSI tumors characterizes a highly immunological subtype in CRC. This 
phenotype presents with topical immune growth control (raised number of cytotoxic tumor 
infiltrating lymphocytes), proximal colon location of tumor, female gender, high-grade tu-
mor, apoptotic behaviour, low number of distant metastases and is of importance to inflam-
matory response and cancer control [127]. MSI is observed in several types of cancers; en-
dometrial, ovarian, urothelial and prostate [128]. CRC and prostate cancer are linked by he-
redity [129]. MSI is used as a biomarker for prognosis and can predict sensitivity to 5-
Fluorouracil (5-FU) in colon cancer [130, 131]. Moreover, MSI reveals genetic heterogeneity 
and expresses frame shift mutated proteins, a unique pool of tumor antigens that can act as T 
cells mediated immunotherapy targets and might have an immunological connection to HLA-
A⃰02 (Figure 11) [132, 133]. 
 
HLA-A*02 genotype  
     
Figure 11.  HLA and MHC presentation. 
Adapted   from Nature Reviews Immunology 
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HLA´s are variant alleles, expressed in all cells of the organism. MHC is the product of a 
HLA gene. The HLA-A*02 genotype is one of the most frequent HLA-A alleles in all ethnic 
populations and the most common haplotype in Sweden (58%) [6]. Red blood cells (no nu-
cleus) and neurons (low antigen presentation) have an explicably lower expression of HLA. 
Cells without HLA expression could be at risk for apoptosis via natural killer (NK) cells acti-
vated by absence of MHC class I. Cancer cells develop mechanisms to escape immune 
recognition. Certain HLA haplotypes are known to correlate to both risk of getting a cancer 
and prognosis in surviving cancer [133]. The loss or down-regulation of MHC class I has 
been studied [81]. The different HLA haplotypes have been associated with patients’ progno-
sis in several cancers e.g. melanoma and ovarian cancer [134]. The locus of HLA is situated 
at chromosome 6 and encodes for peptide-presenting proteins. This is the first step in adap-
tive immunity and protection against foreign pathogens or abnormalities detected in the cell 
and in the organism. T-cells recognize tumor cells through antigen presentation on cell sur-
face regulated by human leucocyte antigen (HLA).  HLA class I molecules, HLA-A, -B, and 
-C, generally present intracellular peptides. The variation of HLA´s is restricted to the exons. 
This polymorphism defines a group of peptides that can potentially bind to a specific MHC 
and respond to infectious or cancer agents [132]. HLA alleles might correlate to other bi-
omarkers or predict response to oncological treatments. HLA´s have been studied in different 
tumors and in colon cancer [133]. When giving immune based therapies to cancer patients, 
the HLA phenotype is correlated with diverse outcomes [132]. Though, immunotherapies 
should not solely rely on HLA class I restricted CD8+ T-cells [132, 135]. 
Two biological hypotheses can be mentioned to justify the selection of HLA-A*02. One hy-
pothesis is that having HLA-A*02 genotype reflects an impairment of the immune response 
to CRC, resulting in a more aggressive disease or that the HLA-A*02 genotype is important 
in late disease where we see the results [81]. The other hypothesis is that inherited “linkage 
disequilibrium”, a cluster of HLA alleles can involve nearby located genes for carcinogenesis 
and immune response. HLA-A*02 are over-represented and is a strong negative prognostic 
factor in ovarian cancer [81]. Prognosticity of HLA-A*02 has also been reported in prostate 
cancer [136]. Its relationship to colon cancer is not known but HLA-A*02 genotype has 
through personal communication of unpublished work been suggested to associate to nega-
tive prognosis in females (Villabona et al. “Analysis of immune-related prognostic markers in 
colon cancer in patients randomized to surgery or surgery and adjuvant cytostatic treatment”, 
submitted 2015). Patients with HLA-A*02 genotype and CRC might have a significant worse 
outcome, however the genotype is not a risk factor [81]. It is probably the combined effect of 
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having HLA-A*02 genotype and loss or down-regulation of HLA class I MHC, that explains 
the poor prognosis.  
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AIMS OF THESIS 
________________________________________________________________________ 
 
 
 
The overall aim of this thesis is to explore the HER3 expression in colon and rectal cancer. 
 
 
The more specific aims are: 
To evaluate the extent of HER3 expression in primary CRC. 
To evaluate the extent of HER3 expression in colorectal cancer metastases. 
To evaluate impact of HER3 on prognosis in colon and rectal cancer. 
To investigate if there are associations between HER3 expression and tumor phenotype, tu-
mor location or outcome of adjuvant chemotherapy in colon and rectal cancer. 
To evaluate the prognostic and predictive effect of combining biomarkers HER3, MMR and 
HLA-A*02 in colon cancer. 
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PATIENTS AND METHODS 
________________________________________________________________________ 
 
Patients 
In paper I, III and IV the tumors derived from 236 respectively, 521 respectively, 493 Swe-
dish patients with radically resected colon and rectal cancer of stage II and III from 29 hospi-
tals in Sweden (Figure 12). Surgery was performed between 1991 and 1997. The follow up 
ended in November of 2004. Surgical tumor specimens (FFPE) originated from an adjuvant 
Nordic trial (n=2224) where patients (≤75 years) with CRC were randomized to either sur-
gery or surgery plus 5-FU based adjuvant chemotherapy [33].  
 
 
Figure 12. Flow chart of patients in paper I-IV.  
In paper II, 107 patients with CRC and liver metastases were included (Figure 12). These 
patients all had resected primary tumors and liver metastases. The patients in this study were 
derived from a population-based cohort (n=255) undergoing liver resection for CRC metasta-
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ses between 2004 and 2009 at the Unit of Hepatobiliary Surgery, Karolinska University Hos-
pital. The primary CRC was resected between 1999 and 2009 in different Swedish Hospitals. 
The FFPE primary tumors (n= 107), corresponding nodal metastases (n=62) and liver metas-
tases (n=107) were collected. Data from patient's medical records were retrieved. 
The Dukes staging system and the stage 0-IV system for colon and rectal cancer were used in 
the pathology reports. The definition of proximal colon location was tumors in the caecum, 
ascending and transverse colon. The definition of distal colon location was the left flexure, 
descending and sigmoid colon. Regarding tumor differentiation, low-grade represents a well 
to moderately differentiated tumor while high-grade represents poor differentiated tumor. The 
definition of disease free survival was time from surgery to recurrence or to death of any 
cause. Clinical data in paper I, III and IV were retrieved from Regional Cancer Centers of 
Epidemiological Oncology in Sweden. 
All studies of the thesis conform to the guidelines for prognostic tumor marker research, the 
REMARK criteria [104] and were approved by the local Ethical Committee at the Karolinska 
Institutet. 
 
Immunohistochemistry (IHC) 
IHC is demonstration of antigens within a tissue section by means of specific antibodies. The 
antigen-antibody complex is visualized by a mix of a secondary antibody, enzyme and a dex-
tran chain which catalyzes a coloring producing reaction [137]. This technique is widely used 
for investigating tumor markers and was used in paper I-IV.  
Immunohistochemical detection of HER3 and MMR expression was performed in primary 
colon or rectal tumors. HER3 expression was also detected in lymph node and liver metasta-
ses. The examined tumor specimens were derived from FFPE in 4-µm slices. A two-step pro-
cedure is described in text below and can be seen in Figure 13 and 14.  
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In step one, tumor sections were deparaffinized in xylene, rehydrated in ethanol and washed 
in distilled water. For antigen retrieval, slides were boiled in Dakos Retrievel (pH 9.0) in a 
pressure cooker (2100 Retriever) and rinsed twice. Endogenous peroxidation in the tumor 
was quenched by treatment with 3% hydroperoxidase. Background staining was reduced by 
incubation in 10% goat serum for 30 minutes. A HER3 monoclonal antibody from rabbit 
(Abcam, SP71 ErbB, ab 93739, dil 1:800) and to detect MMR proteins, MLH-1 respectively 
MSH-2, a mouse immunoglobulin G monoclonal antibody clone G168-15 (BD PharMingen, 
San Diego, CA, USA, dil 1:100) and clone FE11 (Oncogene Research Products, Boston, MA, 
USA, dil:1:100) were added and left over night at +4°C (Figure 13).  
For step two, samples were rinsed and incubated with an amplification system, EnVision™, 
HRP system (DakoCytomation) for 30 minutes (Figure 14). Visualization of staining with 
3,3´-diaminobenzidine tetrahydrochloride (DAB, DakoCytomation) was carried out followed 
by Mayers Haematoxylin staining.  
                          
                                          
 
 
 
 
 
 
Figure 13. First step of IHC. 
Figure 14. Second step of IHC. 
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Scoring  
Slides were evaluated using a light microscope by two independent observers blinded to clin-
ical and pathological data (F.L or K.Ö and M.H). Disagreements (<5%) were reviewed fol-
lowed by conclusive judgement. The entire section of tumor was evaluated and an approxi-
mation was done on the percentage of stained cancer cells. 
 
HER3 
A representative tumor material of good quality and a well working antibody system for 
staining resulted in very few IHC failures. The HER3 receptor is mainly expressed in the cell 
membrane and only a small fraction is present in the cytoplasm [119]. Therefore, grading was 
done of the membrane.  
The intensity of the membrane stain in cancer cells was graded 0-3. Absent stain or occur-
rence of staining of any grade in <10% was categorized as grade 0. Very faint membrane 
stain, present in parts of the membrane, was considered grade 1. Weak to moderate stain that 
was complete (circumferential) in the cell membrane or basolateral, was grade 2 and strong 
stain, complete or basolateral was defined as grade 3 (Figure 15). Cytoplasmic or background 
staining was not graded.  
Grades 0-1 were categorized as low expression and grades 2-3, as high expression of mem-
branous HER3. Staining pattern was scored according to the Hercept test, DAKO interpreta-
tion manual for gastric cancer since no established scoring of HER3 in colorectal cancer ex-
ists.  
    
 HER3, Negative (x10)    HER3, Grade 1 (x20)        HER3, Grade 2 (x40)       HER3, Grade 3 (x20) 
Figure 15. IHC in primary colorectal tumors of HER3 expression, Grade 0-3. Grade 0-1 are 
considered low expression and grade 2-3 as high HER3 expression. 
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MMR 
A case was negative for expression of a given protein (dMMR) if the tumor cells displayed a 
complete absence of nuclear staining with the respective monoclonal antibody. Intact nuclear 
staining of normal tissue (lymphocytes and non-neoplastic stromal cells) close to the tumor 
was used as an internal positive control. The MSH-2 antibody showed a nuclear staining that 
was easy to interpret. The MLH-1 antibody yielded a few cases with patchy, heterogenous 
staining. If nuclear staining existed in the tumor, a case was considered as positive (pMMR). 
Figure 16 shows the IHC of MLH-1 and MSH-2. 
   
 MLH-1 positive (pMMR)        MSH-2 positive (pMMR)             Negative (dMMR) 
Figure 16. IHC in colon tumors of positive and negative stained tumor regarding MLH-1 and 
MSH-2. Magnification x 20. 
 
FISH 
Fluorescence in situ hybridization (FISH) was performed in paper I to clarify if HER3 gene 
amplification or ploidy occurred associated to high HER3 expression. FISH was performed 
in 58 tumors of all grades (a majority of grade 3). 
HER3 detection was done on cut FFPE tumor sections according to standard techniques. 
After application of the HER3 probe (Zytolight HER3/CEN 12) the sections were treated 
with HyBrite programme and finally fluorescent stain (DAPI) was added. Microscope fluo-
rescence scoring was done with Axio Imager Zeiss using filters for DAPI. Each color was 
recorded and processed digitally. Hybridization signal from the stained chromosomal re-
gion of HER3 lit in orange and the hybridization control signal from chromosome 12, lit in 
green. In normal cells, there are two HER3-regions (orange) and two chromosome 12 sig-
nals (green) (Figure 17). 
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                               Normal                         Ploidy                Gene amplification 
Figure 17. FISH 
 
Polymerase chain reaction 
In paper IV, HLA-A*02 genotype was assessed by doing PCR which is a method to amplify 
DNA. When few genes are analyzed in many samples, this is a preferable method.  
DNA was extracted from the same FFPE tumors that were analyzed for HER3 and MMR 
expression by IHC. A High Pure DNA extraction kit (Roche, Molecular Biochemicals, 
Mannheim, Germany) was used, according to manufacturer´s protocol but omitting the 
DNase treatment.  
The presence of HLA-A*02 was determined by genomic amplification with primers specif-
ic for HLA-A*02 (forward A*577LL and reverse A*503invLL). These primers are specific 
for all HLA*A02 alleles except A*020109, 0248, 0250, 0255 which are uncommon in the 
Swedish population. To exclude false negatives due to unamplifiable DNA, all negative 
samples were subjected to amplification of the housekeeping gene S14. Samples negative 
for S14 were excluded. The technique is described in detail in the article by Gamzatova et 
al [134]. 
 
Statistics 
Statistical analyses of the results of paper I-IV were performed using STATISTICA software 
release 10 (StatSoft®, Tulsa, Oklahoma, USA). For HLA-A*02, HER3 and MMR analyses 
in paper IV, StatView for Windows (SAS Institute Inc. Version 5.0.1) was also used. In all 
studies, the χ² test was performed to examine relationship between patient´s demographics, 
tumor characteristics and HER3 expression. In paper I, the Spearman Rank´s correlation test 
was performed for the assessment of correlation of HER3 expression comparing two different 
sections of the same tumor. The same test was used in paper I and II to see correlation be-
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tween HER3 in primary CRC and the corresponding metastases. Survival analyses were per-
formed in all papers using the Kaplan Meier method and differences in survival were tested 
with the log-rank test. In all papers, Gehan-Wilcoxon test and Cox regression was used in the 
univariate analysis to examine correlation between HER3 expression, patient and tumor char-
acteristics for overall survival (OS). Multivariate analysis was performed using Cox propor-
tional hazard regression models in papers I, III and IV. The results were considered signifi-
cant if p<0.05. All graphs in articles I-IV were made in STATISTICA. 
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RESULTS AND DISCUSSION 
________________________________________________________________________ 
 
HER3 expression in primary tumor 
The HER3 expression in primary CRC tumor was hypothized to be elevated. 
In paper I and III, primary colon and rectal tumors of stage II and III were examined regard-
ing HER3 expression. In paper II, CRC with liver meteastases were investigated related to 
HER3 expression. HER3 was detected at high frequency in the cell membrane in colon and 
rectal tumors. The distribution of HER3 expression of grades 0-3 and high and low HER3 
expression can be seen in Table 6. 
 
  
Number of patients 
Study I, n=236 
Number of patients 
Study II, n=107 
Number of patients 
Study III, n=521 
  HER3, 
Grade 0 67 (28%) 14 (13%) 153 (29%) 
 
 
HER3, 
Grade 1 5 (2%) 7 (7%) 21 (4%) 
 
Low expression 
30/20/33% 
 
HER3, 
Grade 2 65 (28%) 47 (44%) 166 (32%) 
 
 HER3, 
Garde 3 99 (42%) 39 (36%) 181 (35%) 
 
High expression 
70/80/67% 
 
Table 6. HER3 expression assessed by IHC in primary colon and rectal tumors, study I-III. 
 
In study I, which was a pilot study, 70% of primary tumors of colon and rectal cancer had a 
high HER3 expression (grade 2-3). When dividing tumor types, high expression was 63% in 
colon cancer and notably, 87.5% in rectal cancer. In 47 tumors HER3 expression was ana-
lyzed in two different areas. The HER3 expression was found to be homogenous and a strong 
correlation between paired samples was seen (r=0.9, p<0.0001).  
A complementary FISH analysis was done in 58 tumors, with different grades of expression. 
We did not find any gene amplification of HER3 but in three tumors of grade 3, we found 
triploidy or tetraploidy. FISH was done to compare with HER2 that regulates through gene 
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amplification. HER2 does not have a known ligand like HER3 and HER2 are dependent on 
gene amplification to function in cancer.  
HER3 seems to work through variation of expression. Over expression of HER3 is observed 
in several cancers but relevance of HER3 somatic mutations in oncogenesis is not completely 
established. Large scale genomic studies reported HER3 mutations in 11% of colon tu-
mors [138]. Functional characterization of the HER3 mutants show that, together with HER2, 
they promote oncogenic signaling in a ligand independent manner. The role of HER3 as an 
obligate partner is well established in some tumors e.g. breast and is currently evaluated in 
other malignancies [116, 121]. 
Study III was an explorative, retrospective study which was enlarged and refined from the 
pilot study. Exclusively colon cancer of stage II and III, related to HER3 expression was in-
cluded. High expression of HER3 (grade 2-3) was seen in 67% of colon tumors. In study II, 
an analysis of CRC with liver meteastases was done and the HER3 expression in the primary 
tumor was 80%. A higher grade of expression in CRC with liver metastases can be explained 
by that we examined a selected group of patients that all had liver metastases, a majority had 
lymph node metastases and a few had lung metastases. This cohort might represent a more 
aggressive and advanced disease.  
 
When we initiated expression studies of HER3 in colon and rectal cancer, the literature was 
not conforming regarding expression [118, 119, 139]. In several reports, cytoplasmatic and 
membranous staining were graded and colon, rectal cancer and mCRC were sometimes 
mixed.  
 
We have used immunohistochemistry to detect HER3 and it is a widely used technique in 
clinical praxis. However, it is a semi quantitative method to detect proteins and it is to some 
extent dependent on the investigators. Validation of our results using another quantitatively 
method (Western blot or mass spectrometry) is recommended but tend to require fresh or 
fresh frozen tumor. The protein quantification methods of HER complex have some draw-
backs but have been done in CRC cells for HER3 [119, 140]. The discrepancies in expres-
sion of HER3 in CRC observed in different studies can be related to multiple causes, i.e. 
different staining protocols, antibodies, fixation time and variation in scoring methods 
(Rajkumar score, Hercept score, other). A weakness in our study is that tumors were col-
lected from several hospitals and specimen routines might differ before paraffin embed-
ding. The original histopathology reports were used but a pathologist review has been done.  
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The IHC scoring and validation of HER3 have not yet reached consensus. We have used the 
Hercept score of gastric cancer as guidelines for grading membrane intensity and change of 
pattern from a basolateral staining to a pathological total loss or circumferential staining. It 
has been easy to interpret the histology of HER3 and the used antibody has been working 
well. The 10% cut of has been chosen according to literature and is suitable for experimental 
expression analysis but in a clinical setting, it should probably be raised. IHC is a good tech-
nique, which is easy and samples from routine histology can be used. Compared to TMA, 
IHC, the whole slide has been analyzed which is a more accurate way if tumors are 
heterogenous. A comment on grading is that grade 1 constituted of very few cases and could 
probably be included in grade 0. The distinction between low and high HER3 expression was 
easy to interpret and is recommended for use in a clinical setting. 
 
HER3 expression in colorectal metastases 
HER3 expression in primary tumor and metastases was hypothized to correlate. 
In paper I, HER3 expression in corresponding lymph node metastases was analyzed from 
patients with CRC of stage III. There was a high HER3 expression (grade 2–3) in 75% of the 
lymph node metastases and a correlation existed between HER3 expression in primary tumor 
and in corresponding lymph node metastases (r=0.6, p<0.0001). In paper II, liver metastases 
were synchronous in 57% of patients and a majority had metastatic lymph nodes at the time 
of primary surgery. All patients had liver metastases of which 82% presented 
high HER3 expression. The expression in lymph node metastases was 81%. 
HER3 expression in primary tumor correlated with expression in corresponding lymph node 
metastases (r=0.65, p<0.001) and in liver metastases (r=0.45, p<0.001). A correlation of 
HER3 expression between the two different metastases was seen as well (r=0.65, p<0.001). A 
comparison of the 107 patients in study II to the original cohort was done and survival was 
the same, indicating no severe skewness.  
In study II, we have monitored HER3 through cancer progression. A selected group is exam-
ined that probably represents a more biologically aggressive disease. When separately analyz-
ing the subgroups of patients with synchronous versus metachronous liver metastases regard-
ing HER3 expression in the primary tumor related to survival, no difference was found alt-
hough that could have been expected. This may be due to the relatively small sample size or 
to actual lack of biological difference.  
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It has been shown that most genetic aberrations in primary tumors are maintained in the CRC 
liver metastases [90]. Synchronicity of primary colon tumor and liver metastases might 
consitute a grave cancer disease but whether there are differences between primaries of syn-
chronous and metachronous groups remain undetermined [88, 89]. When comparing our find-
ing of maintained HER3 status in CRC metastases, it is in analogy with Miglio et al, concern-
ing KRAS mutational status, which is maintained in corresponding CRC metastases [90]. One 
can suppose that there is an underlying oncological advantage of the phenomena regarding 
HER3 and KRAS. 
There is a risk of under staging when less than 12 nodes (metastatic and benign) are analyzed. 
In paper I and III, >11 lymph nodes were analyzed in only 16% of the tumors. In paper II, 
63% of the patients had >11 lymph nodes analyzed. This is a possible reason for under esti-
mation of stage. 
 
HER3 expression and prognosis in colon and rectal cancer 
A high HER3 expression was hypothized to have a negative prognostic value in CRC. 
In paper I, HER3 expression in the primary tumor was an independent prognostic factor for 
overall survival in the entire group of patients (p=0.026 resp. p=0.011, for OS and DFS). A 
high HER3 expression in the primary tumor was associated with worse clinical outcome and 
correlated with stage of disease. HER3 expression was a prognostic factor also in the sub-
group of patients with stage II colon cancer according to OS (p=0.03) but not in colon cancer 
stage III. Neither did HER3 expression have a prognostic value in the small subgroup (n=64) 
of patients with rectal cancer. In the multivariate analysis, stage of disease, differentiation of 
tumor, age and HER3 expression in the primary tumor were independent prognostic factors 
for OS and DFS. 
In paper II, there was no correlation between HER3 expression and OS neither using primary 
surgery, nor liver resection as a reference point. To comment on that, the number of patients 
in study II were low for analyzing prognosis and all patients developed liver metastases.  
In paper III, we observed an independent correlation of distal tumors and HER3 expression 
related to DFS (p=0.03). In the multivariate analysis, a hazard ratio of 0.56 (low vs high 
HER3, 95% CI, 0.31-0.99) (p=0.047) was calculated. HER3 expression in primary colon tu-
mor was not found to be prognostic for OS. Multivariate analysis showed that stage, age and 
number of analyzed lymph nodes ≥12 correlated independently to OS in the entire group of 
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patients. We also found in the univariate model that stage and sex correlated to DFS in distal 
colon tumors but only sex and HER3 expression remained significant after the multivariate 
analysis. 
In study I, HER3 expression was prognostic regarding OS and DFS in the entire group of 
patients and in the subgroup of stage II colon cancer. These findings led to study III. Only 
colon cancer was included to avoid unexpected events of HER3 expression caused by radio-
therapy. In study III, HER3 expression did not prove to be prognostic with respect to OS for 
the entire group of patients but prognostic for DFS in the group of distal colon cancers. 
Why is HER3 expression in distal colon tumors prognostic regarding DFS but not for OS? 
DFS is an approved way of monitoring prognosis in colon cancer [32]. DFS has been used 
and validated in many adjuvant studies, which includes recurrence, all deaths and also sec-
ondary cancers. It is considered relevant to use DFS in studies even if the adjuvant treatment 
does not affect deaths other than of colon cancer. Plausible affecting factors are a low number 
of patients in the different subgroups and that the prognostic power of HER3 is not so strong.  
High HER3 expression has in other studies been validated and found to be an independent 
prognostic factor with decreased OS in colon tumors. Furthermore, inhibition of HER3 in 
CRC cell lines induced apoptosis and reduced cell invasion and cell migration [119]. In a 
meta analysis of HER3 expression assessed by IHC, it was reported that it is a robust prog-
nostic marker with correlation to worse survival in solid tumors [141]. Three CRC studies 
were included, two small studies showed that high HER3 was not prognostic for OS and one 
study showed that high HER3 was prognostic for shortened OS [119, 139].  
 
HER3 phenotype, location and adjuvant therapy 
HER3 expression in primary tumor was hypothized to associate with phenotype, colon loca-
tion and maybe to adjuvant chemotherapy. 
 
Location and grade 
In study III, a high expression of HER3 was seen in 59% of proximal colon tumors versus 
77% of distal tumors and in study I, the expression in rectal cancer was about 88% (Figure 
18). The gradient of HER3 expression and association to tumor localization in the colon and 
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rectum is a novel finding in CRC.  High expression of HER3 was associated with distal colon 
location (p<0.0001), independent of stage. 
 
 
Figure 18. Distributional gradient of high HER3 expression related to proximal, distal colon and 
rectal tumor localization. 
Regarding tumor grade, 71% of low-grade tumors expressed high levels of HER3 compared 
to 49% in the group of high-grade tumors. There was a correlation between low-grade tumor 
and high HER3 expression (p<0.0001) that was significant in the whole group of patients and 
in stage III but not for stage II. A higher amount of distal colon tumors was categorized as 
low-grade cancers 88% compared with 72% in proximal tumors, which was expected in a 
colon cancer materiel. Among low-grade tumors, there was a larger proportion of distal tu-
mors with high HER3 expression (78%) compared with proximal tumors (64%). In multivar-
iate analysis, we found that a higher frequency of distal colon tumors had a high HER3 ex-
pression compared with proximal, independent of tumor grade, OR=2.09 (95% CI, 1.39-3.14) 
(p=0.001). This means that we found that a higher number of distal colon tumors have high 
HER3 expression not only due to that distal tumors are more frequently low-grade tumors. 
This conforms to work by Missiaglia et al where expression of EGFR and HER2 correlated 
with distal tumor location [64].  
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Differences between proximal, distal colon and rectal tumors may have prognostic impact. 
Tumor location reflects biological heterogeneity that might have prognostic and predictive 
potential. The finding that high HER3 expression is more prevalent distally and decreases in 
high-grade tumors might associate inversely with e.g. MSI tumors presenting the relationship 
of proximal location and high-grade tumors. 
In study II, expression of HER3 in the primary tumor did not correlate to any patient or tumor 
characteristics. 
 
Adjuvant treatment 
In study I, we found that patients with rectal cancer treated with pre-operative radiotherapy 
had a higher intra tumoral HER3 expression (97%) compared to non-radiated tumors (78%), 
independent of stage (p=0.023). HER3 expression might increase after radiation indicating 
that radiation itself raises expression. This is an interesting finding for using HER3 inhibitors 
after radiation in a neoadjuvant manner. However, this subgroup (n=64) is small and further 
research is needed to find out if pre-operative radiotherapy may have an impact on HER3 
expression.  
In study I-III, HER3 expression did not predict response to 5-FU based adjuvant chemothera-
py. The study was not designed for this and the benefit of 5-FU based therapy in the original 
Nordic adjuvant trial was only 7% and did not reach significance [33]. 
 
Combining HER3, MMR and HLA-A*02  
We hypothized that a combination of markers would improve prognostic and predictive value 
and associate to tumor location. 
In paper IV, the HER3 and MMR expression were analyzed in primary colon tumors from 
493 patients using IHC. 417 patients were analyzed for HLA-A*02 genotype with PCR. 
 
HER3, MMR, HLA-A*02 
Expression of high HER3 was seen in 66% and deficient MMR was found in 21% of colon 
tumors. The HLA-A*02 genotype was present in 58% of colon tumors. Deficient MMR was 
correlated to proximal colon (p<0.0001) and to high-grade tumors (p=0.01). To have a 
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dMMR tumor was prognostic for a better outcome in the entire group of patients regarding 
OS, which was expected. Female gender was associated to dMMR. There was a correlation 
between high HER3 and proficient MMR expression (p<0.0001). The HLA-A*02 genotype 
was not a prognostic factor in colon cancer. HLA-A*02 was like dMMR, associated to fe-
male gender.  HER3 or MMR and HLA-A*02 did not correlate. Neither could correlation to 
localization of tumor be proven when combining HER3 or MMR and HLA-A*02.  
 
Prognosis and prediction  
Patients with high HER3/pMMR tumors had a worse outcome compared to the low 
HER3/dMMR group. The median OS for these patients were 81 months respectively 87 
months. The adjusted hazard ratio for OS was 1.78 (CI 95%, 1.08-2.95) (p=0.02).  
In patients with high HER3/pMMR tumors receiving adjuvant chemotherapy, a tendency was 
observed to extend DFS (median 84 vs 67 months) compared to the same group treated with 
only surgery, HR=0.75 (CI 95%, 0.54-1.04) (p=0.08). For OS, significance was not reached 
and no effect of adjuvant chemotherapy was seen in other groups.  
In the small subgroup of high HER3/dMMR tumors, reduced DFS (median 30 vs 92 months) 
was observed when patients had a distal tumor (proximal vs distal; HR=0.10 (CI 95%, 0.02-
0.47)) (p=0.007). The same was observed for OS.  
In the subgroup of females with high HER3 expressing tumors of stage III who received sur-
gery only, a decreased OS (median 40 vs 95 months) was seen if the patient had HLA-A*02 
genotype, HR=0.37 (CI 95%, 0.14-0.94) (p=0.03). In analysis of the same subgroup of fe-
male patients with colon tumors of stage III, treated with surgery only, a shortened OS (medi-
an 38 vs 84 months) was observed if patients had the combination of pMMR and HLA-A*02 
genotype compared to dMMR and missing HLA*02, HR=0.14 (CI 95%, 0.03-0.95) (p=0.04). 
Univariate analysis showed that stage, tumor grade, number of analyzed lymph nodes and 
MMR (p=0.02) were significant factors for overall survival. In the multivariate analysis, 
stage, tumor grade, number of analyzed lymph nodes, MMR (p=0.048) and age remained 
significant.  
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Discussion 
Combined biomarkers might offer an individualized approach in colon cancer that can sepa-
rate a surgical curable cancer from a more aggressive disease and identify patients who will 
benefit from adjuvant chemotherapy. A single marker can be a part of the puzzle but lacks 
absolute power to constitute the whole truth of prognosis and prediction in cancer. The heter-
ogeneity of a stepwise developing colon cancer spans through multiple molecular pathways. 
In study IV, we have analyzed markers from different sections of these pathways.  
5-FU based chemotherapy is still golden standard in adjuvant treatment of colon cancer but 
administrative pattern has changed and additional given drugs differ. Even though the origi-
nal adjuvant study and the tumor material are from the nineties, it is still useful for research. 
MMR detection can be done with good accuracy using MLH-1 and MSH-2 with IHC [142].  
In this study we have identified subgroups in which we can anticipate prognosis and observe 
a predictive tendency to adjuvant chemotherapy when combining HER3, MMR and HLA-
A*02 genotype compared to each marker alone. A solitary biomarker or staging did not show 
a tendency of prediction regarding adjuvant chemotherapy in this tumor material before [33, 
143]. High HER3/dMMR expression in a patient´s tumor correlated to distal location and 
resulted in reduced survival. However, this was observed in a small group of patients. When 
looking at patients with distal tumors and high HER3 expression alone in study III, a short-
ened DFS was detected. HER3 is highly expressed in both proximal (59%) and distal colon 
(77%) cancer and dMMR is mainly expressed in proximal colon tumors.  
MMR is an accepted prognostic and predictive biomarker which is used in the clinic. We 
have analyzed our results independent from the effect of MMR status itself. The connection 
to female gender in colon cancer was known for dMMR and suspected for the HLA-A*02 
genotype and might work through synergism when combined. The prognostic value of having 
the HLA-A*02 genotype in patients with colon cancer and association to female gender are 
novel findings (Villabona et al. “Analysis of immune-related prognostic markers in colon 
cancer in patients randomized to surgery or surgery and adjuvant cytostatic treatment”, sub-
mitted 2015). A possible mechanism behind the prognostic trait of HLA-A*02, on a genetic 
level, may be found comparing male and female genetics.   
Deficient MMR tumors are microsatellite instable which leads to generation of immunogenic 
neopeptides. The host antitumoral immune response is of high importance in cancer. Immune 
evasion caused by HLA class I impairment of antigen presentation can be seen in CRC. HLA 
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class II expression in CRC have been studied and in one third of patients with MSI tumors, 
HLA class II was missing [144]. Another mutated dMMR gene and protein, MSH-3, can 
cause an immunogenic frameshift sequence and different dMMR mutated proteins could act 
as targets for peptide based vaccines for therapeutic and preventive purposes [132].  Little is 
known on how HER3 expression in sporadic colon tumors interacts with MMR and HLA-
A*02 genotype. HER2, is over expressed in breast cancer cells and act as targets for CTL´s. 
HER2 expression is reported to correlate to MHC class I and HER2 over expression might 
impair CTL mediated recognition of several HLA-A*02 restricted tumor antigens [83, 132].  
Personalized medicine is to examine individual patients as well as subgroups of patients. It is 
important to pin point patients that do well and do not need unnecessary, extensive surgery or 
expensive, adjuvant chemotherapy which add suffering. It is equally important to identify 
patients that have a bad prognosis where the best available surgical and oncological treat-
ments and extra surveillance are needed. 
In paper IV, a combined analysis of HER3, MMR expression and HLA-A*02 status might 
improve prognosticity in colon cancer of stage II and III. Further studies are needed to find 
out if this combination can predict response to adjuvant 5-FU based chemotherapy in colon 
cancer or is of prognostic value for tumor location. 
 
 
To conclude; In this thesis, we have shown that a majority of colon and rectal tumors and 
metastases over express HER3. There is increasing evidence that HER3 expression in colon 
and rectal cancer can be of importance as a predictive biomarker for biological therapy [124]. 
Anti HER3 agents are in the pipeline of new treatments and needs to be investigated further. 
Individual selection of therapy has been successful in HER2 expressing breast cancer by de-
fining molecular subtypes that respond differently to treatments. This might be applicable for 
CRC, another solid tumor dependent on the HER axis [115]. When resistance to chemothera-
py (5-FU+irinotecan) in mCRC occurs, a patient with HER3 expression in breast cancer can 
benefit from cetuximab treatment [116].  
CRC is composed of different molecular subtypes and the detection of HER complex and 
HER3 can be of importance. Large, randomized studies will be needed to provide the evi-
dence that will enable clinicians to determine optimal treatment of colon respectively rectal 
cancer patients. 
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CONCLUSIONS 
________________________________________________________________________ 
 
 
 
In summary, the conclusions of this thesis are; 
 
 
A high HER3 expression was found in 70% of primary tumors of CRC, stage II and III and in 
75% of corresponding lymph node metastases. High HER3 expression was a negative prog-
nostic factor for clinical outcome.  
A high HER3 expression is seen in about 80% of CRC with liver metastases, in correspond-
ing lymph node and in liver metastases. There was a correlation between HER3 expression in 
primary tumor and different metastases in CRC. 
A high HER3 expression in colon cancer of stage II and III, was associated to distal colon 
location and low-grade tumor. High HER3 expression was of prognostic value according to 
DFS in distal colon cancer.  
A combined analysis of HER3, MMR expression and HLA-A*02 can have a prognostic val-
ue and a tendency to prediction of adjuvant 5-FU based chemotherapy in subgroups of pa-
tients with colon cancer of stage II and III.  
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FUTURE PERSPECTIVES 
________________________________________________________________________ 
  
Two aspects of HER3 expression in CRC and in corresponding metastases are interesting. 
One is that HER3, as a member of the HER complex and well-studied EGFR and HER2 ex-
pression, is not extensively studied in CRC. Further, knowledge of HER3 may definitely con-
tribute to the complete picture of the HER complex and CRC. The second aspect is to look at 
HER3 as a prospect of drug development.  
CRC is a disease of heterogeneous origins. As of today, prognostic and predictive biomarkers 
for CRC are few. A panel of markers selected because of biological hypothesis or biomarker 
screening with e.g. Tissue Micro Array (for gene-protein relationship) is suitable for CRC. 
Sequencing genes are quite easily done in this day and age, protein sequencing, is still a bit 
more complicated but can be done. Individual tumors and metastases can give us lots of in-
formation. In this way, the HER complex could be examnied in CRC.  
The HER3 expression could be analyzed related to WNT signaling that has to do with shape, 
body axis and polarity of the cell as well as proliferation and migration. WNT receptors are 
evolutionary conserved and are present in all organisms. WNT signaling is important in em-
bryogenesis and oncogenesis. Defect WNT is an early event in the adenoma carcinoma se-
quence [97]. The WNT receptor can be analyzed by IHC and also WNT gene products such 
as COX-2 and VEGF. HER3 expression and its connection to WNT might enlighten when 
and how normal HER3 distribution transforms to pathological distribution in a cancer cell. 
This eventual association could represent an early marker of CRC [145, 146]. 
HER3 expression related to the HER3 complex and EGFR inhibitors in mCRC is urgent to 
study since analysis of wildtype or mutated KRAS alone cannot manage the perfect patient 
selection. We have started a biobank of FFPE tumor slides from CRC patients and liver me-
tastases who received modern, oncological treatment. Immunohistochemistry for prognostic 
markers have been done and can be continued in this material. Other techniques like PCR for 
HLA-A*02 can be done from these FFPE tumors and would be interesting to do in this CRC 
material since late stage cancer disease has been linked to HLA-A*02 [81]. In another collab-
oration, where patients with mCRC received cetuximab and irinotecan, we have analyzed 
HER3 expression with IHC but the data collecting is not yet complete. This direction of our 
HER3 research adds a modern and predictive dimension compared to this thesis where a gen-
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eral mapping of HER3 expression in CRC has been done. Further, HER inhibitors are tested 
in clinical trials and it is going to be exciting to see in which tumor type HER3 inhibitors will 
be used first. Colon and especially rectal cancer are good candidates since HER3 is highly 
expressed in 70-88% of patients. A clinical trial with neo adjuvant, HER3 inhibitors, given 
after radiotherapy to rectal cancer patients would be intriguing to realize. It might create a 
new landscape of rectal cancer treatment, if the complete response rate can be adequately 
raised.   
HER3 expression and immune response are sparingly studied in colorectal cancer as of today. 
Maybe HER3 like HER2 can be up and down regulated by HLA antigens and the HLA geno-
type may affect [126, 133]. Antitumoral helper T-cells can raise response in the HER com-
plex in specific immunotherapies and HER3 expression in cetuximab treated patients is of 
interest [147]. Also the relationship between HER3 expression and CD8+ expression can be 
investigated further (detected by IHC and in a clinical setting, TMA-IHC).  
 
Affibody Molecules  
Affibody molecules are small, high affinity binding proteins based on a non-immunoglobulin 
scaffold. In a molecular imaging clinical study, a HER2 binding Affibody molecule have 
been shown to be a promising tool for the diagnosis of HER2 positive metastases in breast 
cancer patients [148] and currently, other Affibody molecules are entering clinical trials.  
In vivo studies have shown specific uptake of high affinity HER3 binding Affibody mole-
cules in HER3-expressing organs and in vitro studies have shown inhibition of HER3 signal-
ing [149]. These findings may indicate a future potential of Affibody molecules as therapy of 
HER3 related cancers, including colorectal cancer.  
The main challenge in HER3 imaging in cancer is the relatively low receptor expression in 
tumors and expression of HER3 also in normal tissue [150]. This may be partially circum-
vented by using a high affinity HER3 binding agent and/or pre-administration of a non-
labeled agent. An advantage of Affibody molecules over antibodies for use in imaging in-
clude the rapid distribution and tissue penetration, as well as fast clearance of unbound mole-
cule, providing high contrast images within hours (Figure 19).  
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                A               B   
 
Figure 19.  A; Immunofluorescence staining of HER3 receptors expressed on the surface of ade-
nocarcinoma cells with Affibody molecules (green fluorescence). Adapted from Affibody AB with 
permission.  
B; Ribbon diagram of the three-dimensional structure of an Affibody molecule.   
 
For therapeutic applications, the small size and high solubility of Affibody molecules is bene-
ficial, as it allows higher molar doses per volume, which also opens up for alternative means 
of administration. Moreover, Affibody molecules used as a therapeutic alternative to antibod-
ies might bypass problems of acquired resistance observed for antibody based drugs.  
Affibody molecules may be used to detect biomarkers and follow their actions in the tumor. 
One may also use them in mCRC to detect immediate and late effects of HER3 binding and 
inhibition of the HER complex. The high affinity of affibody molecules can be used in desir-
able, irreversible inhibition, which can reduce tumor cell growth [149]. Furthermore, imme-
diate response of HER3 targeting and inhibition of a tumor in a clinical setting might be ob-
tained with PET imaging compared to the delayed effects of chemotherapy and evaluating 
computed tomography. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
________________________________________________________________________ 
 
Cancer är efter hjärt-kärl sjukdom den näst vanligaste orsaken till död i Sverige. Tjock- och 
ändtarmscancer kallas kolorektal cancer (CRC). Hos kvinnor är det den näst vanligaste tu-
mörformen och hos män, den tredje vanligaste. Så är fallet både i Sverige och i ett globalt 
perspektiv. Vad vi äter, fysisk aktivitet, tobaksanvändning, alkoholintag, levnadsmiljö och 
ärftlighet är faktorer som kan inverka på om man får kolorektal cancer eller inte. Dessa fakto-
rer är viktiga var och en för sig men kan också samverka och har betydelse även då sjukdo-
men brutit ut. Om man får en tumör i tjock- eller ändtarm är det viktigt att man opererar bort 
den. Prognosen är bättre om sjukdomen upptäcks tidigt i förloppet. Tilläggsbehandling i form 
av strålning, cellgifter eller antikroppar kan bli aktuellt beroende på sjukdomstyp. Även dot-
tersvulster, metastaser i lunga och lever i begränsad form kan opereras bort idag. Cellgift får 
man för att döda enstaka cirkulerande tumörceller i kroppen. Med denna omfattande behand-
ling förbättras prognosen och patienten kan till och med bli friskförklarad. Operation av en 
tumör och cellgift är gamla men fortfarande viktiga behandlingsprinciper. Det är ändå ange-
läget att hitta nya sätt att angripa och besegra cancer. Nya läkemedel med bättre och mer pre-
cis verkan och mindre biverkan behövs, särskilt då tumören spritt sig. 
HER3 är ett naturligt protein som sitter på cellers yta. Här utövar den kontroll av olika funk-
tioner som till exempel tillväxt. HER3 är en receptor vilket betyder att den kan ”öppnas” av 
en ligand och stängas, ungefär som ett nyckellås. Då det är öppet startas livsviktiga, kemiska 
reaktioner i cellen. Antalet receptorer på cellens yta kan öka och minska. HER3 ingår i en 
familj av 4 receptorer med liknande funktioner, vilka samarbetar inbördes. Tillväxt, kärlbild-
ning och cellers rörlighet regleras av HER3 i fosterlivet, i normal tarm och i en tarmtumör. 
HER3 mönstret i cellen ändras mellan frisk och sjukt på ett karakteristiskt sätt. 
I den här avhandlingen var syftet att studera förekomsten av HER3 i CRC samt i lymfkörtel- 
och levermetastaser. HER3 förekomst i CRC var då dessa studier inleddes, relativt okänd. 
Kartläggningen av HER3 används till att visa hur stor andel av CRC som har ett avvikande 
mönster och hur detta påverkar överlevnad och val av behandling. Vi har använt en teknik 
som benämns immunohistokemi för att kartlägga HER3. Man färgar HER3 med hjälp av en 
antikropp, en kemisk reaktion och färg. Tumörerna graderas i mikroskop i hög och låg före-
komst.  
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Resultat och konklusion av denna avhandling blev att förekomsten av hög HER3 är 67% i 
tjocktarmscancer och 88% i ändtarmscancer. Om man har hög förekomst av HER3 i sin tu-
mör, har man det sannolikt även i metastaser. Hög HER3 förekomst kan eventuellt kopplas 
till en sämre prognos men mer forskning och studier med fler patienter behövs innan man kan 
vara helt säker. HER3 förekomsten är högre i slutet av tjocktarmen och ändtarmen jämfört 
med i början, vilket inte var känt sen tidigare. I slutet av tarmen är därför förekomst av HER3 
av större värde för prognos än i början. Vi har kombinerat HER3 förekomst med två andra 
potentiella markörer för CRC. Teorin bakom en kombination av markörer är att man ska 
kunna få en mer precis bedömning genom samverkan. Dessa heter MMR och HLA-A*02. 
MMR är viktig för cellers DNA reparation vilken ofta störs i cancer. HLA-A*02 är en gentyp 
som har med immunförsvaret att göra. Den skulle kunna inverka på så sätt att immunförsva-
ret inte bekämpar tumören som brukligt. Resultatet blir att en mer aggressiv tumör utvecklas 
än om man inte har gentypen. Med kombinerade markörer kunde patientgrupper med bäst 
respektive sämst prognos identifieras. De med sämst prognos ska då ha den bästa tänkbara 
kirurgin, onkologisk behandling och tät uppföljning. Så skulle sjukdomsåterfall och död kun-
na undvikas.  
HER3 förekomsten är hög i CRC vilket gör den till ett utmärkt mål för skräddarsydd, indivi-
duell behandling. Eventuellt har även hög HER3 förekomst en negativ inverkan på prognos. 
Studier för att kunna blockera eller ”låsa” HER3 i tumörer och därmed förhindra cancerväxt 
pågår men än finns ingen medicin mot HER3 på apoteket. 
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